E
Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
E
Sell
9/18/2023Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 9/18/2023 due to a substantial decline in the growth index, solvency index and volatility index. EBIT declined 88.1% from -$1.31M to -$2.46M, earnings per share declined from -$0.6632 to -$1.2026, and total revenue declined 20.81% from $2.52M to $1.99M.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 9/18/2023 due to a substantial decline in the growth index, solvency index and volatility index. EBIT declined 88.1% from -$1.31M to -$2.46M, earnings per share declined from -$0.6632 to -$1.2026, and total revenue declined 20.81% from $2.52M to $1.99M.
D
Sell
7/12/2023Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E+ on 7/12/2023 due to a significant increase in the growth index, volatility index and efficiency index. Total revenue increased 215.5% from $798.1 to $2.52M, earnings per share increased from -$2.081 to -$0.6632, and EBIT increased 68.07% from -$4.1M to -$1.31M.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E+ on 7/12/2023 due to a significant increase in the growth index, volatility index and efficiency index. Total revenue increased 215.5% from $798.1 to $2.52M, earnings per share increased from -$2.081 to -$0.6632, and EBIT increased 68.07% from -$4.1M to -$1.31M.
E
Sell
11/21/2022Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 11/21/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.09 to -$0.67, EBIT declined 273.9% from -$1.66M to -$6.21M, and total revenue declined 134.82% from $4.19M to -$1.46M.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 11/21/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.09 to -$0.67, EBIT declined 273.9% from -$1.66M to -$6.21M, and total revenue declined 134.82% from $4.19M to -$1.46M.
D
Sell
8/15/2022Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to D- from D on 8/15/2022 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.01 to -$0.09.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to D- from D on 8/15/2022 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.01 to -$0.09.
D
Sell
5/18/2022Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D from E+ on 5/18/2022 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 384.27% from -$867.2 to $2.47M, the quick ratio increased from 0.87 to 2.14, and earnings per share increased from -$0.5787 to -$0.01.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D from E+ on 5/18/2022 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 384.27% from -$867.2 to $2.47M, the quick ratio increased from 0.87 to 2.14, and earnings per share increased from -$0.5787 to -$0.01.
E
Sell
4/18/2022Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D on 4/18/2022 due to a significant decline in the growth index and total return index. Operating cash flow declined 585.51% from -$1.21M to -$8.3M, earnings per share declined from -$0.1727 to -$0.5787, and total revenue declined 140.43% from $2.15M to -$867.2.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D on 4/18/2022 due to a significant decline in the growth index and total return index. Operating cash flow declined 585.51% from -$1.21M to -$8.3M, earnings per share declined from -$0.1727 to -$0.5787, and total revenue declined 140.43% from $2.15M to -$867.2.
D
Sell
1/3/2022Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D from D- on 1/3/2022 due to an increase in the total return index.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D from D- on 1/3/2022 due to an increase in the total return index.
D
Sell
11/17/2021Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E+ on 11/17/2021 due to a significant increase in the growth index, solvency index and valuation index. Debt to equity declined from 0.18 to 0.1, operating cash flow increased 36.24% from -$1.9M to -$1.21M, and earnings per share increased from -$0.22 to -$0.1727.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E+ on 11/17/2021 due to a significant increase in the growth index, solvency index and valuation index. Debt to equity declined from 0.18 to 0.1, operating cash flow increased 36.24% from -$1.9M to -$1.21M, and earnings per share increased from -$0.22 to -$0.1727.
E
Sell
11/8/2021Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
9/1/2021Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E on 9/1/2021 due to an increase in the solvency index. Debt to equity declined from 0.25 to 0.18.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to D- from E on 9/1/2021 due to an increase in the solvency index. Debt to equity declined from 0.25 to 0.18.
E
Sell
5/24/2021Upgraded
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to E from E- on 5/24/2021 due to an increase in the volatility index, growth index and solvency index. Earnings per share increased from -$0.4917 to $0.3085, operating cash flow increased 90.13% from -$4.52M to -$446.6, and EBIT increased 49.11% from -$4.32M to -$2.2M.
Petros Pharmaceuticals, Inc. (PTPI) was upgraded to E from E- on 5/24/2021 due to an increase in the volatility index, growth index and solvency index. Earnings per share increased from -$0.4917 to $0.3085, operating cash flow increased 90.13% from -$4.52M to -$446.6, and EBIT increased 49.11% from -$4.32M to -$2.2M.
E
Sell
4/8/2021Downgrade
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E- from E on 4/8/2021 due to a decline in the volatility index.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E- from E on 4/8/2021 due to a decline in the volatility index.
E
Sell
4/6/2021None
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E from U on 04/06/2021.
Petros Pharmaceuticals, Inc. (PTPI) was downgraded to E from U on 04/06/2021.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
